Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 660 participants.
Also called NCT01462266
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 660 participants
- Sponsor
- Registry
-
NCT01462266
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Completed
Technical summary
Registry record NCT01462266. Randomized; double masking; primary purpose treatment. Start 2012-01-13 (actual); primary completion 2013-06-06 (actual). Results posted on 2014-04-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Sitagliptin
- Intervention (Drug)
- Comparator: Placebo
- Intervention (Biological)
- Insulin Glargine
- Intervention (Drug)
- Metformin
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01462266- Content hash
6a763d476f59f192c15d2d89f781f3a6efea12fc8d0e673a7b36a5d1f2759952